Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 6/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4008609 | 0.88 | KMT2A (0.65) | SMN1; SMN2GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL1413288 | 0.86 | SMN1; SMN2 (0.68) | SMN1; SMN2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL665198 | 0.83 | MEN1 (0.87) | SMN1; SMN2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL6710105 | 0.82 | MEN1 (0.70) | SMN1; SMN2GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL664021 | 0.79 | KMT2A (1.00) | SMN1; SMN2MEN1KMT2AMAPTLMNA | |
| SCHEMBL5791144 | 0.79 | MEN1 (0.66) | SMN1; SMN2GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL17319243 | 0.78 | KMT2A (0.69) | SMN1; SMN2GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL1495069 | 0.78 | MCL1 (0.69) | SMN1; SMN2MEN1KMT2AMAPTHPGD | |
| SCHEMBL29682974 | 0.78 | MEN1 (0.77) | SMN1; SMN2GAAMEN1KMT2AALDH1A1 | |
| SCHEMBL395744 | 0.78 | MEN1 (0.77) | SMN1; SMN2GAAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7276516-B2 | CB1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-10-02 | — | — | US | claimed |
| JP-2007519631-A | — | — | 2007-07-19 | — | — | JP | claimed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | claimed |
| EP-1699761-A1 | CB1 MODULATOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-09-13 | — | — | EP | claimed |
| WO-2005066126-A1 | CB1 MODULATOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | claimed |
| EP-1699761-B1 | CB1 MODULATOR COMPOUNDS | LILLY CO ELI (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7595339-B2 | CB1 modulator compounds | ELI LILLY AND COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080287504-A1 | CB1 MODULATOR COMPOUNDS | ALLEN JENNIFER REBECCA | 2008-11-20 | — | — | US | disclosed |
| US-7276516-B2 | CB1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-10-02 | — | — | US | disclosed |
| US-20070088018-A1 | Cb1 antagonist compounds | ELI LILLY AND COMPANY (US) | 2007-04-19 | — | — | US | disclosed |
| EP-1699761-A1 | CB1 MODULATOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005066126-A1 | CB1 MODULATOR COMPOUNDS | ELI LILLY AND COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088018-A1 | Cb1 antagonist compounds | CNR1, CNR2, CHRNA5 | SMN1; SMN2 546/4885GAA 1347/4885MEN1 157/4885 |
| US-20080287504-A1 | CB1 MODULATOR COMPOUNDS | CNR1, CNR2, MAG | SMN1; SMN2 628/4885GAA 1364/4885MEN1 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.